4th Aug 2014 17:59
4 August 2014
Immunodiagnostic Systems Holdings PLC
AGM Results
Immunodiagnostic Systems Holdings PLC ("IDS" or "the Company" or "the Group"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces the results of its Annual General Meeting (the "Meeting") that was held at 2 p.m. today.
Trading update
Dr Anthony Martin, Non-executive Chairman, provided a business update at the Meeting and a copy of the trading statement has been made available on the Company's website.
Voting Results
All resolutions put to the meeting were decided by way of a poll and all were duly passed except for the resolution to approve the Remuneration Report.
For information, details of the votes cast on the poll are shown below:
Resolution | Votes For | Votes For (as % of votes cast) | Votes Against (as % of votes cast) | Votes Withheld |
1. To receive the accounts for the financial year ended 31 March 2014 together with the reports of the Directors and of the Auditor thereon. | 18,624,257 | 100.00 | 0.00 | 628 |
2. To declare a final dividend for the financial year ended 31 March 2014. | 15,829,633 | 100.00 | 0.00 | 2,795,252 |
3. To re-elect as a Director of the Company Dr Edward Blair. | 15,829,633 | 84.99 | 15.01 | 0 |
4. To re-elect as a Director of the Company Mr Roland Sackers. | 18,609,256 | 99.92 | 0.08 | 0 |
5. To re-appoint Ernst & Young LLP as Auditor of the Company.
| 18,624,885 | 100.00 | 0.00 | 0 |
6. To authorise the Directors of the Company to determine the remuneration of the Auditor of the Company. | 18,624,885 | 100.00 | 0.00 | 0 |
7. To approve the Directors' remuneration report for the financial year ended 31 March 2014. | 7,886,671 | 49.83 | 50.17 | 2,796,472 |
8. To authorise the Directors to allot relevant securities. | 18,623,657 | 100.00 | 0.00 | 1,228 |
9. To authorise the disapplication of pre-emption rights in accordance with section 570 of the Companies Act 2006. | 18,609,277 | 99.92 | 0.08 | 600 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the IDS website (www.idsplc.com).
For further information:
Immunodiagnostic Systems Holdings PLC | Tel : +44 (0)191 519 0660 |
Patrik Dahlen, Chief Executive Officer | |
Chris Yates, Finance Director | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Clare Terlouw | |
FTI Consulting | Tel : +44 (0)203 727 1000 |
Simon Conway | |
Mo Noonan |
About Immunodiagnostic Systems Holdings PLC
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.
Related Shares:
IDH.L